Search

Your search keyword '"Vikas, Praveen"' showing total 36 results
Start Over Author "Vikas, Praveen"
36 results on '"Vikas, Praveen"'

2. Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

Author

Burstein, Harold J, Somerfield, Mark R, Barton, Debra L, Dorris, Ali, Fallowfield, Lesley J, Jain, Dharamvir, Johnston, Stephen RD, Korde, Larissa A, Litton, Jennifer K, Macrae, Erin R, Peterson, Lindsay L, Vikas, Praveen, Yung, Rachel L, and Rugo, Hope S

Subjects
Cancer, Estrogen, Clinical Research, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Biomarkers, Tumor, Breast Neoplasms, Female, Humans, Molecular Targeted Therapy, Practice Guidelines as Topic, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.MethodsAn Expert Panel conducted a systematic review to identify new, potentially practice-changing data.ResultsFifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations.RecommendationsAlpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, ABC, or MBC following prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. Clinicians should use next-generation sequencing in tumor tissue or cell-free DNA in plasma to detect PIK3CA mutations. If no mutation is found in cell-free DNA, testing in tumor tissue, if available, should be used as this will detect a small number of additional patients with PIK3CA mutations. There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. For BRCA1 or BRCA2 mutation carriers with metastatic HER2-negative breast cancer, olaparib or talazoparib should be offered in the 1st-line through 3rd-line setting. A nonsteroidal aromatase inhibitor (AI) and a CDK4/6 inhibitor should be offered to postmenopausal women with treatment-naïve HR-positive MBC. Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting.Additional information can be found at www.asco.org/breast-cancer-guidelines.

Published
2021

3. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

Author

Choueiri, Toni K., Labaki, Chris, Bakouny, Ziad, Hsu, Chih-Yuan, Schmidt, Andrew L., de Lima Lopes, Gilberto, Jr., Hwang, Clara, Singh, Sunny R.K., Jani, Chinmay, Weissmann, Lisa B., Griffiths, Elizabeth A., Halabi, Susan, Wu, Ulysses, Berg, Stephanie, O'Connor, Timothy E., Wise-Draper, Trisha M., Panagiotou, Orestis A., Klein, Elizabeth J., Joshi, Monika, Yared, Fares, Dutra, Miriam Santos, Gatson, Na Tosha N., Blau, Sibel, Singh, Harpreet, Nanchal, Rahul, McKay, Rana R., Nonato, Taylor K., Quinn, Ryann, Rubinstein, Samuel M., Puc, Matthew, Mavromatis, Blanche H., Vikas, Praveen, Faller, Bryan, Zaren, Howard A., Del Prete, Salvatore, Russell, Karen, Reuben, Daniel Y., Accordino, Melissa K., Friese, Christopher R., Mishra, Sanjay, Rivera, Donna R., Shyr, Yu, Farmakiotis, Dimitrios, and Warner, Jeremy L.

Published
2023
Full Text
View/download PDF

4. Rural comprehensive cancer care: Qualitative analysis of current challenges and opportunities.

Author

Evans, Sydney, Seaman, Aaron T., Johnson, Erin C., Engelbart, Jacklyn M., Gao, Xiang, Vikas, Praveen, Phadke, Sneha, Schroeder, Mary C., Lizarraga, Ingrid M., and Charlton, Mary E.

Subjects
HEALTH services accessibility, COMMUNITY health services, MEDICAL quality control, RESEARCH funding, QUALITATIVE research, ACADEMIC medical centers, CANCER patient medical care, RURAL hospitals, INTERVIEWING, DECISION making in clinical medicine, CONTINUING medical education, RURAL health services, EXPERIENCE, THEMATIC analysis, RURAL population, RURAL conditions, RESEARCH methodology, URBAN hospitals, CANCER patient psychology, ONCOLOGISTS, URBAN health
Abstract

Purpose: While limited resources can make high‐quality, comprehensive, coordinated cancer care provision challenging in rural settings, rural cancer patients often rely on local hospitals for care. To develop resources and strategies to support high‐quality local cancer care, it is critical to understand the current experiences of rural cancer care physicians, including perceived strengths and challenges of providing cancer care in rural areas. Methods: Semi‐structured interviews were conducted with 13 cancer providers associated with all 12 non‐metropolitan/rural Iowa hospitals that diagnose or treat >100 cancer patients annually. Iterative thematic analysis was conducted to develop domains. Findings: Participants identified geographic proximity and sense of community as strengths of local care. They described decision‐making processes and challenges related to referring patients to larger centers for complex procedures, including a lack of dedicated navigators to facilitate and track transfers between institutions and occasional lack of respect from academic physicians. Participants reported a desire for strengthening collaborations with larger urban/academic cancer centers, including access to educational opportunities, shared resources and strategies to collect and monitor data on quality, and clinical trials. Conclusions: Rural cancer care providers are dedicated to providing high‐quality care close to home for their patients and would welcome opportunities to increase collaboration with larger centers to improve coordination and comprehensiveness of care, collect and monitor data on quality of care, and access continuing education opportunities. Further research is needed to develop implementation approaches that will extend resources, services, and expertise to rural providers to facilitate high‐quality cancer care for all cancer patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline

Author

Vikas, Praveen, primary, Messersmith, Hans, additional, Compton, Carolyn, additional, Sholl, Lynette, additional, Broaddus, Russell R., additional, Davis, Anjee, additional, Estevez-Diz, Maria, additional, Garje, Rohan, additional, Konstantinopoulos, Panagiotis A., additional, Leiser, Aliza, additional, Mills, Anne M., additional, Norquist, Barbara, additional, Overman, Michael J., additional, Sohal, Davendra, additional, Turkington, Richard C., additional, and Johnson, Tyler, additional

Published
2023
Full Text
View/download PDF

6. Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria

Author

Shrode, Rachel, primary, Knobbe, Jessica, additional, Cady, Nicole, additional, Yadav, Meeta, additional, Hoang, Jemmie, additional, Cherwin, Catherine, additional, Curry, Melissa, additional, Garje, Rohan, additional, Vikas, Praveen, additional, Sugg, Sonia, additional, Phadke, Sneha, additional, Filardo, Edward, additional, and Mangalam, Ashutosh, additional

Published
2022
Full Text
View/download PDF

8. Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA Vaccines

Author

Choueiri, Toni K., primary, Labaki, Chris, additional, Bakouny, Ziad, additional, Hsu, Chih-Yuan, additional, Schmidt, Andrew L., additional, de Lima Lopes, Gilberto, additional, Hwang, Clara, additional, Singh, Sunny R.K., additional, Jani, Chinmay, additional, Weissmann, Lisa B., additional, Griffiths, Elizabeth A., additional, Halabi, Susan, additional, Wu, Ulysses, additional, Berg, Stephanie, additional, O’Connor, Timothy E., additional, Wise-Draper, Trisha M., additional, Panagiotou, Orestis A., additional, Klein, Elizabeth J., additional, Joshi, Monika, additional, Dutra, Miriam Santos, additional, Gatson, Na Tosha N., additional, Blau, Sibel, additional, Singh, Harpreet, additional, Nanchal, Rahul, additional, McKay, Rana R., additional, Nonato, Taylor K., additional, Quinn, Ryann, additional, Rubinstein, Samuel M., additional, Puc, Matthew, additional, Mavromatis, Blanche H., additional, Vikas, Praveen, additional, Faller, Bryan, additional, Zaren, Howard A., additional, Del Prete, Salvatore, additional, Russell, Karen, additional, Reuben, Daniel Y., additional, Accordino, Melissa, additional, Friese, Christopher R., additional, Mishra, Sanjay, additional, Rivera, Donna R., additional, Shyr, Yu, additional, Farmakiotis, Dimitrios, additional, and Warner, Jeremy L., additional

Published
2022
Full Text
View/download PDF

10. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Author

Schneider, Bryan J., primary, Naidoo, Jarushka, additional, Santomasso, Bianca D., additional, Lacchetti, Christina, additional, Adkins, Sherry, additional, Anadkat, Milan, additional, Atkins, Michael B., additional, Brassil, Kelly J., additional, Caterino, Jeffrey M., additional, Chau, Ian, additional, Davies, Marianne J., additional, Ernstoff, Marc S., additional, Fecher, Leslie, additional, Ghosh, Monalisa, additional, Jaiyesimi, Ishmael, additional, Mammen, Jennifer S., additional, Naing, Aung, additional, Nastoupil, Loretta J., additional, Phillips, Tanyanika, additional, Porter, Laura D., additional, Reichner, Cristina A., additional, Seigel, Carole, additional, Song, Jung-Min, additional, Spira, Alexander, additional, Suarez-Almazor, Maria, additional, Swami, Umang, additional, Thompson, John A., additional, Vikas, Praveen, additional, Wang, Yinghong, additional, Weber, Jeffrey S., additional, Funchain, Pauline, additional, and Bollin, Kathryn, additional

Published
2021
Full Text
View/download PDF

11. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Author

Santomasso, Bianca D., primary, Nastoupil, Loretta J., additional, Adkins, Sherry, additional, Lacchetti, Christina, additional, Schneider, Bryan J., additional, Anadkat, Milan, additional, Atkins, Michael B., additional, Brassil, Kelly J., additional, Caterino, Jeffrey M., additional, Chau, Ian, additional, Davies, Marianne J., additional, Ernstoff, Marc S., additional, Fecher, Leslie, additional, Funchain, Pauline, additional, Jaiyesimi, Ishmael, additional, Mammen, Jennifer S., additional, Naidoo, Jarushka, additional, Naing, Aung, additional, Phillips, Tanyanika, additional, Porter, Laura D., additional, Reichner, Cristina A., additional, Seigel, Carole, additional, Song, Jung-Min, additional, Spira, Alexander, additional, Suarez-Almazor, Maria, additional, Swami, Umang, additional, Thompson, John A., additional, Vikas, Praveen, additional, Wang, Yinghong, additional, Weber, Jeffrey S., additional, Bollin, Kathryn, additional, and Ghosh, Monalisa, additional

Published
2021
Full Text
View/download PDF

12. t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma

Author

Nadiminti, Kalyan, Silverman, Margarida, Bhagavathi, Sharathkumar, and Vikas, Praveen

Subjects
atypical t(15, 17), FISH, primary myelofibrosis, case report, cytogenetics
Abstract

Background primary myelofibrosis (PMF) is a myeloproliferative neoplasm which is associated with clonal molecular and cytogenetic abnormalities (CA) and varied clinical manifestations. While various CA have been previously described, t(15; 17) has not been reported in association with this condition. Case presentation A 69-year-old male presented with constitutional symptoms, cytopenias and bone marrow biopsy revealed immature blasts with fibrosis. Cytogenetic analysis showed a t(15;17) which initially suggested a diagnosis of acute promyelocytic leukemia (APL). However, flourescence in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) studies were negative for transcripts promyelocytic leukemia (PML) gene and retinoic acid receptor alpha (RARA) or PML-RARA fusion. Along with these results, a second review of bone marrow histology, flowcytometry and the detection of a calreticulin gene (CALR) mutation helped with the correct diagnosis of PMF. Patient was then treated with ruxolitinib, a JAK (Janus kinase) 1 and 2 inhibitor, and eventually proceeded to receive a matched unrelated reduced intensity conditioning (RIC) allogeneic stem cell transplantation (ASCT) and has been doing well at the 6-month follow up. Conclusions Our case highlights two points, that the t(15;17) is diagnostic of Acute Promyelocytic Leukemia (APL) in most cases, there are exceptions and it can be associated with other malignancies without causing any APL like features, as noted in this case. Also, that t(15; 17) by itself is never sufficient to diagnose APL without confirmation by other methods and relying solely on cytogenetics without timely confirmatory tests can lead to risks of delay in diagnosis and appropriate management.

Published
2019

15. Repurposing Anti-Cancer Drugs for COVID-19 Treatment

Author

Borcherding,Nicholas, Jethava,Yogesh, and Vikas,Praveen

Subjects
Drug Design, Development and Therapy
Abstract

Nicholas Borcherding,1– 4 Yogesh Jethava,1,5 Praveen Vikas1,5 1Holden Comprehensive Cancer Center, University of Iowa, College of Medicine, Iowa City, IA, USA; 2Department of Pathology, University of Iowa, College of Medicine, Iowa City, IA, USA; 3Cancer Biology Graduate Program, University of Iowa, College of Medicine, Iowa City, IA, USA; 4Medical Scientist Training Program, University of Iowa, College of Medicine, Iowa City, IA, USA; 5Department of Internal Medicine, University of Iowa, College of Medicine, Iowa City, IA, USACorrespondence: Praveen VikasHolden Comprehensive Cancer Center, 5983 JPP, 200 Hawkins Drive, Iowa City, Iowa 52242, USATel + 1 319-356-2757Email praveen-vikas@uiowa.eduAbstract: The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards identifying effective drugs and developing novel vaccines. Early data from Adaptive COVID-19 Treatment Trials (ACTT) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and compassionate use study have shown promise for remdesivir, leading to emergency authorization by the Food and Drug Administration (FDA) for treatment of hospitalized COVID-19 patients. However, several randomized studies have now shown no benefit or increased adverse events associated with remdesivir treatment. Drug development is a time-intensive process and requires extensive safety and efficacy evaluations. In contrast, drug repurposing is a time-saving and cost-effective drug discovery strategy geared towards using existing drugs instead of de novo drug discovery. Treatments for cancer and COVID-19 often have similar goals of controlling inflammation, inhibiting cell division, and modulating the host microenvironment to control the disease. In this review, we focus on anti-cancer drugs that can potentially be repurposed for COVID-19 and are currently being tested in clinical trials.Keywords: COVID-19, drug-repurposing, anti-cancer drugs

Published
2020

17. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, primary, Aboulafia, David M., additional, Accordino, Melissa K., additional, Acoba, Jared D., additional, Ahluwalia, Manmeet S., additional, Ahmad, Syed A., additional, Ajmera, Archana, additional, Alimohamed, Saif I., additional, Altman, Jessica, additional, Angevine, Anne H., additional, Bakouny, Ziad, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill S., additional, Barrow McCollough, Briana, additional, Bashir, Babar, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios S., additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bhutani, Divaya, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Bishnoi, Rohit, additional, Blau, Sibel, additional, Bohachek, Pamela, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bouganim, Nathaniel, additional, Bowles, Daniel W., additional, Busser, Fiona J., additional, Butt, Omar, additional, Cabal, Angelo, additional, Cabalona, Wilhelmina D., additional, Cabebe, Elwyn C., additional, Caimi, Paolo, additional, Campian, Jian L., additional, Carducci, Theresa M., additional, Chen, James L., additional, Cheng, Alex, additional, Chism, David D., additional, Choueiri, Toni K., additional, Clark, Melanie J., additional, Clement, Jessica M., additional, Connors, Jean M., additional, Cook, Erin, additional, Curran, Catherine R., additional, Daher, Ahmad, additional, Dailey, Mark E., additional, Davis, Elizabeth J., additional, Dawsey, Scott J., additional, Deeken, John F., additional, Del Prete, Salvatore A., additional, Demetri, George D., additional, Desai, Aakash, additional, Doroshow, Deborah B., additional, Durbin, Eric B., additional, Egan, Pamela C., additional, Elias, Rawad, additional, Elkrief, Arielle, additional, Elms, Destry J., additional, Elshoury, Amro, additional, Faller, Bryan, additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Ferrario, Cristiano, additional, Fiala, Mark A., additional, Flora, Daniel B., additional, French, Benjamin, additional, Friese, Christopher R., additional, Fu, Julie C., additional, Gadgeel, Shirish M., additional, Gainor, Justin, additional, Galsky, Matthew D., additional, Gantt, Gerald, additional, Garcia, Jorge A., additional, Gartrell, Benjamin A., additional, Gatti-Mays, Margaret E., additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Glover, Michael J., additional, Goel, Sanjay, additional, Graber, Jerome J., additional, Griffiths, Elizabeth A., additional, Grivas, Petros, additional, Grover, Punita, additional, Gulati, Anthony P., additional, Gulati, Shuchi, additional, Gupta, Shilpa, additional, Gurley, Michael, additional, Hafez, Navid, additional, Halabi, Susan, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hausrath, Daniel J., additional, Hawley, Jessica E., additional, Hennessy, Cassandra, additional, Herbst, Roy S., additional, Hershman, Dawn L., additional, Hoppenot, Claire, additional, Hoskins, Kent F., additional, Hoyo-Ulloa, Irma, additional, Hsu, Emily, additional, Hsu, Chih-Yuan, additional, Hwang, Clara, additional, Islam, Jessica Yasmine, additional, Jabbour, Salma K., additional, Jani, Chinmay, additional, Jha, Alokkumar, additional, Jhawar, Sachin R., additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kasi, Anup, additional, Kelleher, Kaitlin, additional, Kennecke, Hagen F., additional, Khaki, Ali Raza, additional, Khan, Hina, additional, Khan, Mahir, additional, Kharofa, Jordan, additional, Kloecker, Goetz, additional, Knoble, Jeanna L., additional, Kulkarni, Amit A., additional, Kumar, Vaibhav, additional, Lammers, Philip E., additional, Leighton, John C., additional, Lemmon, Christopher A., additional, Lewis, Mark A., additional, Li, Ang, additional, Li, Xuanyi, additional, Liu, Stephen V., additional, Lo, K.M., additional, Loaiza-Bonilla, Arturo, additional, Logan, Barbara B., additional, Loggers, Elizabeth T., additional, de Lima Lopes, Gilberto, additional, Loree, Jonathan M., additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Lyman, Gary H., additional, Lynch, Ryan C., additional, Madhavan, Subha, additional, Mahadevan, Daruka, additional, Mahmood, Sana Z., additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, Masters, Tyler, additional, Mavromatis, Blanche H., additional, McKay, Rana R., additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Menendez, Alvaro G., additional, Menon, Harry, additional, Mesa, Ruben A., additional, Mico, Vasil, additional, Miller, Chaim, additional, Mishra, Sanjay, additional, Monahan, Ryan S., additional, Morgans, Alicia K., additional, Mulcahy, Mary F., additional, Mundt, Daniel, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Nakasone, Elizabeth S., additional, Nakayama, John M., additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan H., additional, Nizam, Amanda, additional, Nohria, Anju, additional, Nuzzo, Pier Vitale, additional, Ohri, Nitin, additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Painter, Corrie A., additional, Palmer, Joshua D., additional, Panagiotou, Orestis A., additional, Park, Cathleen, additional, Pasquinelli, Mary M., additional, Patel, Jaymin M., additional, Patel, Kanishka G., additional, Peddi, Prakash, additional, Pennell, Nathan A., additional, Peters, Solange, additional, Pilar, Christine, additional, Pillainayagam, Clement, additional, Puc, Matthew, additional, Ramirez, Amelie G., additional, Rathmann, Joerg, additional, Ravindranathan, Deepak, additional, Reid, Sonya A., additional, Reuben, Daniel Y., additional, Revankar, Sanjay G., additional, Reynolds, Kerry L., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riess, Jonathan, additional, Rini, Brian I., additional, Rink, Cameron, additional, Rosen, Lane R., additional, Rosenstein, Lori J., additional, Rosovsky, Rachel P., additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Rubinstein, Samuel M., additional, Saif, M. Wasif, additional, Salazar, Mary, additional, Santos Dutra, Miriam, additional, Schapira, Lidia, additional, Schmidt, Andrew L., additional, Schroeder, Brett A., additional, Schwartz, Gary K., additional, Schwartz, Candice, additional, Schweizer, Michael T., additional, Serrano, Oscar K., additional, Shafer, Danielle A., additional, Shah, Pankil K., additional, Shah, Dimpy, additional, Shah, Mansi R., additional, Shah, Sumit A., additional, Shah, Chintan, additional, Shaw, Grace, additional, Shaya, Justin A., additional, Shyr, Yu, additional, Slosky, David A., additional, Smits, Melissa, additional, Solorzano, Carmen C., additional, Stauffer, Karen, additional, Stockerl-Goldstein, Keith E., additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Streckfuss, Mitrianna, additional, Subbiah, Suki, additional, Tachiki, Lisa, additional, Tadesse, Eyob, additional, Thompson, Michael A., additional, Topaloglu, Umit, additional, Tucker, Matthew D., additional, Van Allen, Eliezer M., additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta K., additional, Verma, Amit, additional, Vikas, Praveen, additional, Vinayak, Shaveta, additional, Vinh, Donald C., additional, Wagner, Michael J., additional, Wall, Sarah, additional, Wang, Lucy L., additional, Warner, Jeremy L., additional, Wehbe, Firas H., additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Weissmann, Lisa B., additional, Wildes, Tanya M., additional, Williams, Nicole, additional, Wise-Draper, Trisha M., additional, Wood, William A., additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Xu, Wenxin, additional, Yeh, Albert C., additional, Yu, Irene S., additional, Yu, Peter Paul, additional, Zacks, Rosemary, additional, Zaman, Qamar Ul, additional, Zaren, Howard, additional, Zhang, Tian, additional, Zhou, Alice Y., additional, Zhu, Huili, additional, Zon, Rebecca L., additional, and Zubiri, Leyre, additional

Published
2020
Full Text
View/download PDF

18. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.

Author

Kalra, Maitri, Henry, Elizabeth, McCann, Kelly, Karuturi, Meghan S., Alvarez, Jean G. Bustamante, Parkes, Amanda, Wesolowski, Robert, Mei Wei, Mougalian, Sarah S., Durm, Gregory, Qin, Angel, Schonewolf, Caitlin, Trivedi, Meghna, Armaghani, Avan J., Wilson, Frederick H., Iams, Wade T., Turk, Anita A., Vikas, Praveen, Cecchini, Michael, and Lubner, Sam

Published
2022
Full Text
View/download PDF

20. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, primary, Choueiri, Toni K, additional, Shah, Dimpy P, additional, Shyr, Yu, additional, Rubinstein, Samuel M, additional, Rivera, Donna R, additional, Shete, Sanjay, additional, Hsu, Chih-Yuan, additional, Desai, Aakash, additional, de Lima Lopes, Gilberto, additional, Grivas, Petros, additional, Painter, Corrie A, additional, Peters, Solange, additional, Thompson, Michael A, additional, Bakouny, Ziad, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios, additional, Bilen, Mehmet A, additional, Bouganim, Nathaniel, additional, Larroya, Mateo Bover, additional, Castellano, Daniel, additional, Del Prete, Salvatore A, additional, Doroshow, Deborah B, additional, Egan, Pamela C, additional, Elkrief, Arielle, additional, Farmakiotis, Dimitrios, additional, Flora, Daniel, additional, Galsky, Matthew D, additional, Glover, Michael J, additional, Griffiths, Elizabeth A, additional, Gulati, Anthony P, additional, Gupta, Shilpa, additional, Hafez, Navid, additional, Halfdanarson, Thorvardur R, additional, Hawley, Jessica E, additional, Hsu, Emily, additional, Kasi, Anup, additional, Khaki, Ali R, additional, Lemmon, Christopher A, additional, Lewis, Colleen, additional, Logan, Barbara, additional, Masters, Tyler, additional, McKay, Rana R, additional, Mesa, Ruben A, additional, Morgans, Alicia K, additional, Mulcahy, Mary F, additional, Panagiotou, Orestis A, additional, Peddi, Prakash, additional, Pennell, Nathan A, additional, Reynolds, Kerry, additional, Rosen, Lane R, additional, Rosovsky, Rachel, additional, Salazar, Mary, additional, Schmidt, Andrew, additional, Shah, Sumit A, additional, Shaya, Justin A, additional, Steinharter, John, additional, Stockerl-Goldstein, Keith E, additional, Subbiah, Suki, additional, Vinh, Donald C, additional, Wehbe, Firas H, additional, Weissmann, Lisa B, additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth, additional, Xie, Zhuoer, additional, Yeh, Albert, additional, Yu, Peter P, additional, Zhou, Alice Y, additional, Zubiri, Leyre, additional, Mishra, Sanjay, additional, Lyman, Gary H, additional, Rini, Brian I, additional, Warner, Jeremy L, additional, Abidi, Maheen, additional, Acoba, Jared D., additional, Agarwal, Neeraj, additional, Ahmad, Syed, additional, Ajmera, Archana, additional, Altman, Jessica, additional, Angevine, Anne H., additional, Azad, Nilo, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill, additional, Barrow, Briana, additional, Bashir, Babar, additional, Belenkaya, Rimma, additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bestvina, Christine, additional, Bishnoi, Rohit, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bowles, Daniel W., additional, Busser, Fiona, additional, Cabal, Angelo, additional, Caimi, Paolo, additional, Carducci, Theresa, additional, Casulo, Carla, additional, Chen, James L., additional, Clement, Jessica M, additional, Chism, David, additional, Cook, Erin, additional, Curran, Catherine, additional, Daher, Ahmad, additional, Dailey, Mark, additional, Dahiya, Saurabh, additional, Deeken, John, additional, Demetri, George D., additional, DiLullo, Sandy, additional, Duma, Narjust, additional, Elias, Rawad, additional, Faller, Bryan, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Friese, Christopher R., additional, Fu, Paul, additional, Fu, Julie, additional, Futreal, Andy, additional, Gainor, Justin, additional, Garcia, Jorge, additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Grothey, Axel, additional, Gulati, Shuchi, additional, Gurley, Michael, additional, Halmos, Balazs, additional, Herbst, Roy, additional, Hershman, Dawn, additional, Hoskins, Kent, additional, Jain, Rohit K., additional, Jabbour, Salma, additional, Jha, Alokkumar, additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kelleher, Kaitlin, additional, Kharofa, Jordan, additional, Khan, Hina, additional, Knoble, Jeanna, additional, Koshkin, Vadim S., additional, Kulkarni, Amit A., additional, Lammers, Philip E., additional, Leighton, John C., additional, Lewis, Mark A., additional, Li, Xuanyi, additional, Li, Ang, additional, Lo, K.M. Steve, additional, Loaiza-Bonilla, Arturo, additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Mahadevan, Daruka, additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry Jennifer, additional, Handy Marshall, Catherine, additional, Mashru, Sandeep H., additional, Matar, Sara, additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Mehnert, Janice M., additional, Menendez, Alvaro, additional, Menon, Harry, additional, Messmer, Marcus, additional, Monahan, Ryan, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Naidoo, Jarushka, additional, Nakayama, John M., additional, Narayan, Vikram, additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan, additional, Nuzzo, Pier Vitale, additional, Oberstein, Paul E., additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Pasquinelli, Mary M., additional, Philip, John, additional, Prabhakaran, Sabitha, additional, Puc, Matthew, additional, Ramirez, Amelie, additional, Rathmann, Joerg, additional, Revankar, Sanjay G., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riely, Gregory J., additional, Riess, Jonathan, additional, Rink, Cameron, additional, Robilotti, Elizabeth V., additional, Rosenstein, Lori, additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Saif, M. Wasif, additional, Sanyal, Amit, additional, Schapira, Lidia, additional, Schwartz, Candice, additional, Serrano, Oscar, additional, Shah, Mansi, additional, Shah, Chintan, additional, Shaw, Grace, additional, Shergill, Ardaman, additional, Shouse, Geoffrey, additional, Soares, Heloisa P., additional, Solorzano, Carmen C., additional, Srivastava, Pramod K., additional, Stauffer, Karen, additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Subbiah, Vivek, additional, Tamimi, Rulla, additional, Tannir, Nizar M., additional, Topaloglu, Umit, additional, Van Allen, Eli, additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta, additional, Verma, Amit K., additional, Vikas, Praveen, additional, Wall, Sarah, additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Wise-Draper, Trisha, additional, Wood, William A., additional, Xu, Wenxin (Vincent), additional, Yackzan, Susan, additional, Zacks, Rosemary, additional, Zhang, Tian, additional, Zimmer, Andrea J., additional, and West, Jack, additional

Published
2020
Full Text
View/download PDF

22. The clinical promise of immunotherapy in triple-negative breast cancer

Author

Vikas,Praveen, Borcherding,Nicholas, and Zhang,Weizhou

Subjects
Cancer Management and Research
Abstract

Praveen Vikas,1,2 Nicholas Borcherding,2–5 Weizhou Zhang2–5 1Department of Internal Medicine, College of Medicine, University of Iowa, Iowa City, IA, USA; 2Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA; 3Department of Pathology, College of Medicine, University of Iowa, Iowa City, IA, USA; 4Cancer Biology Graduate Program, College of Medicine, University of Iowa, Iowa City, IA, USA; 5Medical Scientist Training Program, College of Medicine, University of Iowa, Iowa City, IA, USA Abstract: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poorer outcomes compared to other breast cancer subtypes. Contributing to the worse prognosis in TNBC is the higher rates of relapse and rapid progression after relapse. Advances in targeted therapeutics and conventional chemotherapy for TNBC have been stymied due to the lack of specific targets. Moreover, the responses to chemotherapy in TNBC lack durability, partially accounting for the higher rates of relapse. Immunotherapy, notably immune-checkpoint blockade, has shown to improve survival and maintain robust antitumor responses in both hematologic and solid malignancies. Unlike lung cancer, melanoma, and bladder cancer, most breast cancers are not inherently immunogenic and typically have low T cell infiltration. However, among breast cancer subtypes, TNBC is characterized by greater tumor immune infiltrate and higher degree of stromal and intratumoral tumor-infiltrating lymphocytes (TILs), a predictive marker for responses to immunotherapy. Moreover, in TNBC, the high number of stromal TILs is predictive of more favorable survival outcomes and response to chemotherapy. Immunotherapy is being extensively explored in TNBC and clinical trials are showing some promising results. This article focuses on the rationale for immunotherapy in TNBC, to explore and discuss preclinical data, results from early clinical trials, and to summarize some ongoing trials. We will also discuss the potential application of immunotherapy in TNBC from a clinician’s perspective. Keywords: triple-negative breast cancer, immunotherapy, PD-1/PDL-1 antibody, CTLA-4 antibody, checkpoint inhibitors, cancer vaccines

Published
2018

23. t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma

Author

Nadiminti,Kalyan, Silverman,Margarida, Bhagavathi,Sharathkumar, Vikas,Praveen, Nadiminti,Kalyan, Silverman,Margarida, Bhagavathi,Sharathkumar, and Vikas,Praveen

Abstract

Kalyan Nadiminti,1 Margarida Silverman,1 Sharathkumar Bhagavathi,2 Praveen Vikas11Division of Hematology and Blood and Marrow Transplantation, University of Iowa Hospital and Clinics, Iowa City, IA, USA; 2Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USABackground: primary myelofibrosis (PMF) is a myeloproliferative neoplasm which is associated with clonal molecular and cytogenetic abnormalities (CA) and varied clinical manifestations. While various CA have been previously described, t(15; 17) has not been reported in association with this condition.Case presentation: A 69-year-old male presented with constitutional symptoms, cytopenias and bone marrow biopsy revealed immature blasts with fibrosis. Cytogenetic analysis showed a t(15;17) which initially suggested a diagnosis of acute promyelocytic leukemia (APL). However, flourescence in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) studies were negative for transcripts promyelocytic leukemia (PML) gene and retinoic acid receptor alpha (RARA) or PML-RARA fusion. Along with these results, a second review of bone marrow histology, flowcytometry and the detection of a calreticulin gene (CALR) mutation helped with the correct diagnosis of PMF. Patient was then treated with ruxolitinib, a JAK (Janus kinase) 1 and 2 inhibitor, and eventually proceeded to receive a matched unrelated reduced intensity conditioning (RIC) allogeneic stem cell transplantation (ASCT) and has been doing well at the 6-month follow up.Conclusions: Our case highlights two points, that the t(15;17) is diagnostic of Acute Promyelocytic Leukemia (APL) in most cases, there are exceptions and it can be associated with other malignancies without causing any APL like features, as noted in this case. Also, that t(15; 17) by itself is never sufficient to diagnose APL without confirmation by other methods and relying solely on cytogenetics without timely confirmatory tests can lead t

Published
2019

24. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline

Author

Henry, N. Lynn, primary, Somerfield, Mark R., additional, Abramson, Vandana G., additional, Ismaila, Nofisat, additional, Allison, Kimberly H., additional, Anders, Carey K., additional, Chingos, Diana T., additional, Eisen, Andrea, additional, Ferrari, Bruno L., additional, Openshaw, Thomas H., additional, Spears, Patricia A., additional, Vikas, Praveen, additional, and Stearns, Vered, additional

Published
2019
Full Text
View/download PDF

26. A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Author

Strouse, Christopher, primary, Nadiminti, Kalyan, additional, Claus, Jillna, additional, Berns, Gabrielle, additional, Schultz, Allyson, additional, Mott, Sarah L., additional, Vikas, Praveen, additional, Tomasson, Michael, additional, Farooq, Umar, additional, Silverman, Margarida, additional, and Jethava, Yogesh, additional

Published
2019
Full Text
View/download PDF

27. Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Author

Nadiminti, Kalyan, primary, Strouse, Christopher, additional, Sidiqi, M Hasib, additional, Dozeman, Lindsay, additional, Mott, Sarah L., additional, Schultz, Allyson, additional, Claus, Jillna, additional, Vikas, Praveen, additional, Farooq, Umar, additional, Tomasson, Michael, additional, Silverman, Margarida, additional, and Jethava, Yogesh, additional

Published
2019
Full Text
View/download PDF

28. Challenges of rural cancer care in the United States

Author

Charlton, Mary, Schlichting, Jennifer, Chioreso, Catherine, Ward, Marcia, and Vikas, Praveen

Subjects
United States. Centers for Medicare and Medicaid Services, Health insurance industry, Cancer patients -- Care and treatment, Palliative treatment, Health care industry, Social workers, Health care industry, Health, American Society of Clinical Oncology
Abstract

Rural cancer patients face many challenges in receiving care, including limited availability of cancer treatments and cancer support providers (oncologists, social workers, mental healthcare providers, palliative care specialists, etc), transportation barriers, financial issues, and limited access to clinical trials. Oncologists and other cancer care providers experience parallel challenges in delivering care to their rural cancer patients. Although no one approach fully addresses the many challenges of rural cancer care, a number of promising strategies and interventions have been developed that transcend the issues associated with long travel distances. These include outreach clinics, virtual tumor boards, teleoncology and other telemedicine applications, workforce recruitment and retention initiatives, and provider and patient education programs. Given the projected increase in demand for cancer care due to the aging population and increasing number of Americans with health insurance through the Affordable Care Act, expansion of these efforts and development of new approaches are critical to ensure access to high-quality care., Introduction One-fifth of the US population resides in rural areas, but only one-tenth of all physicians practice in rural areas. [1] Medical students and residents often opt to stay in [...]

Published
2015

29. A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Author

Nadiminti, Kalyan, primary, Strouse, Christopher, additional, Vikas, Praveen, additional, Dozeman, Lindsay, additional, Schultz, Allyson, additional, Berns, Gabrielle, additional, Claus, Jillna, additional, Mott, Sarah L, additional, Farooq, Umar, additional, Silverman, Margarida, additional, Tomasson, Michael, additional, Zhan, Fenghuang, additional, and Jethava, Yogesh, additional

Published
2018
Full Text
View/download PDF

30. Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Author

Nadiminti, Kalyan, primary, Strouse, Christopher, additional, Vikas, Praveen, additional, Dozeman, Lindsay, additional, Schultz, Allyson, additional, Mott, Sarah L, additional, Claus, Jillna, additional, Farooq, Umar, additional, Silverman, Margarida, additional, Tomasson, Michael, additional, Zhan, Fenghuang, additional, Jethava, Yogesh, additional, and Tricot, Guido J., additional

Published
2018
Full Text
View/download PDF

33. Engaging Stakeholders in the Development of an eHealth Intervention for Cancer Symptom Management for Rural Residents.

Author

Gilbertson‐White, Stephanie, Saeidzadeh, Seyedehtanaz, Tykol, Hannah, Yeung, Chi W., Vikas, Praveen, and Cannon, Ashley

Subjects
TUMOR treatment, ATTITUDE (Psychology), CANCER patient medical care, CONSUMER attitudes, INTERVIEWING, WEB development, RESEARCH methodology, MEDICAL needs assessment, MEDICAL personnel, NEEDS assessment, RURAL health services, SELF-management (Psychology), SURVEYS, TELEMEDICINE, TUMOR classification, DISEASE management, QUALITATIVE research, PATIENTS' attitudes, STAKEHOLDER analysis
Abstract

Background: Late‐stage cancer diagnoses disproportionately occur in rural residents, frequently resulting in increased need for symptom management support with minimal access to these services. Oncology Associated Symptoms and Individualized Strategies (OASIS) is an eHealth symptom self‐management intervention that was developed to provide cancer symptom self‐management support and address this disparity. Purpose: To engage stakeholders about the symptom management needs and concerns of patients with advanced cancer living in rural areas. Methods: A 3‐phased, mixed‐methods design was used to (1) assess stakeholder needs and opinions; (2) develop a symptom self‐management website; and (3) obtain usability feedback from potential users. Interviews with stakeholders (patients and clinic staff) from rural areas using a descriptive qualitative approach were analyzed; cross‐cutting themes were identified; a symptom management web application was developed; and stakeholders completed a 12‐item usability survey about the web application. Results: Patients (n = 16) and clinical staff (n = 10) participated in phase 1. Three major themes were identified: "symptom experience," "symptom management," and "technology." Through an iterative process using these results and evidence from the literature, the OASIS web application was developed. Usability testing with N = 126 stakeholders demonstrated that the web application is easy to use, contains relevant content, and has pleasing graphics. No differences were found among patients, family/friends, and staff. Both frequent and infrequent internet users positively evaluated the web application. Conclusions: Rural stakeholders report significant symptom management needs, are interested in eHealth technologies, and perceived OASIS positively. Future research is needed to evaluate the feasibility, acceptability, and efficacy of OASIS. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

35. Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer.

Author

Maharjan, Chandra K., Mo, Jiao, Wang, Lei, Kim, Myung-Chul, Wang, Sameul, Borcherding, Nicholas, Vikas, Praveen, and Zhang, Weizhou

Subjects
INFLAMMATION prevention, BREAST tumor prevention, PROTEINS, CHRONIC diseases, ESTROGEN, ESTROGEN receptors, CELLULAR signal transduction
Abstract

Simple Summary: Estrogens regulate key physiological functions in the human body, including the development of female reproductive organs. However, dysregulated estrogen signaling—mainly mediated by estrogen receptors (ER)—is associated with many developmental, mental, and other diseases, including cancer. An increasing number of studies have demonstrated that estrogen modulates inflammatory processes within many tissues. In addition to estrogens made within the body, humans are also constantly exposed to many outside estrogens, naturally occurring in plants and those artificially synthesized in industries. Here, we will also discuss the link between chronic exposure to environmental estrogens with tissue inflammation and breast cancer development. The oncogenic role of estrogen receptor (ER) signaling in breast cancer has long been established. Interaction of estrogen with estrogen receptor (ER) in the nucleus activates genomic pathways of estrogen signaling. In contrast, estrogen interaction with the cell membrane-bound G-protein-coupled estrogen receptor (GPER) activates the rapid receptor-mediated signaling transduction cascades. Aberrant estrogen signaling enhances mammary epithelial cell proliferation, survival, and angiogenesis, hence is an important step towards breast cancer initiation and progression. Meanwhile, a growing number of studies also provide evidence for estrogen's pro- or anti-inflammatory roles. As other articles in this issue cover classic ER and GPER signaling mediated by estrogen, this review will discuss the crucial mechanisms by which estrogen signaling influences chronic inflammation and how that is involved in breast cancer. Xenoestrogens acquired from plant diet or exposure to industrial products constantly interact with and alter innate estrogen signaling at various levels. As such, they can modulate chronic inflammation and breast cancer development. Natural xenoestrogens generally have anti-inflammatory properties, which is consistent with their chemoprotective role in breast cancer. In contrast, synthetic xenoestrogens are proinflammatory and carcinogenic compounds that can increase the risk of breast cancer. This article also highlights important xenoestrogens with a particular focus on their role in inflammation and breast cancer. Improved understanding of the complex relationship between estrogens, inflammation, and breast cancer will guide clinical research on agents that could advance breast cancer prevention and therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between.

Author

Han HS, Vikas P, Costa RLB, Jahan N, Taye A, and Stringer-Reasor EM

Subjects
Humans, Immunotherapy, Triple Negative Breast Neoplasms drug therapy
Abstract

Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy. More recently, immunotherapy is approved to treat TNBC, but managing immune-rated adverse events while balancing efficacy is a challenge. The purpose of this review is to highlight the current treatment recommendations for early-stage TNBC and the management of immunotherapy toxicities.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results